Matteo Zignol

Biographic Data

ID6636337
NAMEMatteo Zignol
GIVEN NAMESMatteo
FAMILY NAMEZignol
SIGNATUREZIGNOL M
AFFILIATIONSWorld Health Organization
ORCID0000-0003-0516-3346
VERIFIEDYes
TOTAL WORKS7
TOTAL CITATIONS1
WORKS AS AUTHOR7
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2008
LATEST PUBLICATION YEAR2025
H-INDEX1

  • WHO target product profile for TB detection at peripheral settings

    Open AccessMikashmi Kohli, Alexei Korobitsyn et al.ARTICLEPLOS Global Public Health2025

    In 2014, the World Health Organization (WHO) published target product profiles (TPPs) which detailed minimal and optimal criteria to address high-priority TB diagnostic needs. Since then, the TB community’s needs have evolved; there has been a surge in new and innovative platforms suggesting use of alternative non-invasive specimens for TB diagnosis. This updated TPP used evidence-based modelling to guide the decision-making process for specific …

  • The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

    Open AccessAllison Portnoy, Rebecca A Clark et al.ARTICLEBMJ Global Health2023

    INTRODUCTION: One in two patients developing tuberculosis (TB) in low-income and middle-income countries (LMICs) faces catastrophic household costs. We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles. METHODS: We modelled the impact of introducing TB vaccines meeting the World Health Organization preferred product characteristics…

  • Achieving universal access to rapid tuberculosis diagnostics

    Open AccessNazir Ismail, Carl-Michael Nathanson et al.ARTICLEBMJ Global Health2023

  • Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres

    Open AccessEmily Lai-Ho MacLean, Paolo Miotto et al.ARTICLEPLOS Global Public Health2023

    There were approximately 10 million tuberculosis (TB) cases in 2020, of which 500,000 were drug-resistant. Only one third of drug-resistant TB cases were diagnosed and enrolled on appropriate treatment, an issue partly driven by a lack of rapid, accurate drug-susceptibility testing (DST) tools deployable in peripheral settings. In 2014, World Health Organization (WHO) published target product profiles (TPPs) which detailed minimal and optimal cri…

  • Lifesaving, cost-saving

    Open AccessAashta Gupta, Sandeep Juneja et al.ARTICLEPLOS Global Public Health2022

    Aastha Gupta is a consultant to the Global Alliance for TB Drug Development (TB Alliance), a non-profit organization dedicated to the discovery and development of improved TB therapeutics

  • Implementation of a national anti-tuberculosis drug resistance survey in Tanzania

    Open AccessTimothy M Chonde, Basra Doulla et al.ARTICLEBMC Public Health2008

    Careful preparation of the survey, timing of planned activities, a strong emphasis on data capture tools and data management, and timely supervision are essential for a proper implementation of a national drug resistance survey

  • Limitations on Human Rights

    Open AccessAndrea Boggio, Matteo Zignol et al.ARTICLEHealth and Human Rights2008Cited by: 1

    Tuberculosis, in all its forms, poses a serious, demonstrable threat to the health of countless individuals as well as to health as a public good. MDR-TB and, in particular, the emergence of XDR-TB, have re-opened the debate on the importance, and nature, of treatment supervision for basic TB control and the management of drug-resistant TB. Enforcing compulsory measures regarding TB patients raises questions of respect for human rights. Yet, inte…